KPRX — KIORA PHARMACEUTICALS INC (Healthcare >> Biotechnology)
KPRX FAQ
What is KPRX's P/E ratio?
KIORA PHARMACEUTICALS INC (KPRX) currently trades at a P/E ratio of 428.21.
What is KPRX's ROE?
KIORA PHARMACEUTICALS INC reports a Return on Equity (ROE) of -79.37%.
What is KPRX's dividend yield?
KIORA PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is KPRX's Deepscope Quality Score?
Deepscope rates KPRX's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KPRX?
Deepscope's AI Timing Score for KPRX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KPRX belong to?
KIORA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.63
Price
0.04
(1.54%)
Day Change
|
|
|---|
KPRX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 8) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.63 |
| PBV / Sector |
0.82 / 4.79
GREAT
|
| Earning Per Share | -2.53 |
| PE / Sector |
428.21 / 17.89
|
| PEG or PE/Growth / Sector |
-2.67 / 0.56
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-11 09:55:11 |
| Symbol | KPRX |
| Name | KIORA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.48 / 8,963.32 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024
Phone: 858 224 9600
Website: https://www.kiorapharma.com
Sector: Healthcare >> Biotechnology
Description: Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google